These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21895036)

  • 21. Regulatory review intervals for ophthalmic new drug applications at the US Food and Drug Administration.
    Novack GD
    Am J Ophthalmol; 1998 Jul; 126(1):122-6. PubMed ID: 9683158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
    Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
    Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
    Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.
    Mehrotra N; Bhattaram A; Earp JC; Florian J; Krudys K; Lee JE; Lee JY; Liu J; Mulugeta Y; Yu J; Zhao P; Sinha V
    Drug Metab Dispos; 2016 Jul; 44(7):924-33. PubMed ID: 27079249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.
    Eshera N; Itana H; Zhang L; Soon G; Fadiran EO
    Am J Ther; 2015; 22(6):435-55. PubMed ID: 25621972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(133):39588-611. PubMed ID: 18850675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The conduct of clinical trials and good clinical practices: the sponsor's perspective. Food and Drug Administration.
    Robb EJ; Davis DD; Farrington DO
    J Anim Sci; 1995 Feb; 73(2):614-9; discussion 619-21. PubMed ID: 7601798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine INDs: review of clinical holds.
    Miller DL; Ross JJ
    Vaccine; 2005 Jan; 23(9):1099-101. PubMed ID: 15629351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
    Shulman SR; Brown JS
    Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug Exposure to Establish Pharmacokinetic-Response Relationships in Oncology.
    Solans BP; Garrido MJ; Trocóniz IF
    Clin Pharmacokinet; 2020 Feb; 59(2):123-135. PubMed ID: 31654368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA advisory committees and the new drug approval process.
    Kaitin KI; Melville A; Morris B
    J Clin Pharmacol; 1989 Oct; 29(10):886-90. PubMed ID: 2592579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The FDA Breakthrough-Drug Designation - Four Years of Experience.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacometric Modeling of Naloxegol Efficacy and Safety: Impact on Dose and Label.
    Al-Huniti N; Zhou D; Xu H; Aksenov S; Bui KH; Fox R; Helmlinger G; Stanski D
    Clin Pharmacol Ther; 2017 Nov; 102(5):741-744. PubMed ID: 28548207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of modeling and simulation to integrate clinical pharmacology knowledge across a new drug application.
    Gobburu JV; Sekar VJ
    Int J Clin Pharmacol Ther; 2002 Jul; 40(7):281-8. PubMed ID: 12139204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A program to provide regulatory support for investigator-initiated clinical research.
    Arbit HM; Paller MS
    Acad Med; 2006 Feb; 81(2):146-53. PubMed ID: 16436575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacometrics 2020.
    Gobburu JV
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):151S-157S. PubMed ID: 20881229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018.
    Heyward J; Moore TJ; Chen J; Meek K; Lurie P; Alexander GC
    Ann Intern Med; 2020 Dec; 173(12):956-963. PubMed ID: 32986486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Charging for investigational drugs under an investigational new drug application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.